Lean - Page 14
Stories from Lean come first, newest first, then stories from connected topics (mathematics, AI Science & Health, research, AI, AI for science, Anthropic), each labelled with where it comes from. This view is not indexed by search engines.
Latest
Xaira Says Its X-Scientist AI Matched Human Scientists at Picking Gene Targets
Xaira has unveiled X-Scientist, an agentic AI platform for drug discovery. Its lab test hit rate matched human curation, which it calls initial evidence.
Anthropic’s Draft IPO Filing Shows $16.3bn Half-Year Revenue, WSJ Reports
Anthropic made $16.3bn in first-half revenue and lost $80.7bn, mostly non-cash, a draft IPO prospectus seen by the WSJ shows. It is not public.
UW and NVIDIA Release Open RFD4-Proteina Protein Design Model
UW's Institute for Protein Design and NVIDIA have released RFD4-Proteina, an open model they say is 5-10x better on benchmarks. No paper is cited yet.
OpenAI Says GPT-Rosalind Agents Mined a Brain Atlas in 32 Minutes
OpenAI, PerturbAI and Scripps say 1,946 GPT-Rosalind agents turned a mouse-brain CRISPR atlas into research leads in 32 minutes. Lab tests come next.
Radical Numerics Claims First AI-Designed Phage Given to a Patient
Radical Numerics says phages designed by its new Omnii-1 model were given to a patient with resistant E. coli. It has disclosed no outcome or peer review.
OpenAI Buys Orchestra Bio to Put Drug-Programme Agents in Rosalind
OpenAI has bought Orchestra Bio, whose AI agents track studies and timelines in drug development, to fold into its Rosalind life-sciences suite. No price.
Anthropic Says Claude Designed Binders Against Scorpion Neurotoxins
Anthropic says Claude designed protein binders against scorpion neurotoxins, with 17 of 211 tested designs meeting its criteria. It claims no antivenom.
Eric Schmidt Owns Around 1% of Anthropic Ahead of Its IPO, Bloomberg Reports
Former Google CEO Eric Schmidt owns around 1% of Anthropic from a Series A investment, Bloomberg reports, citing people familiar, ahead of the IPO.
Anthropic Could Double Its Nscale Bet With a Second $45bn Deal, Reports Say
Nscale is reportedly in talks to sell Anthropic about $45bn more of AI computing power from a second West Virginia building, Bloomberg and Reuters report.
Lilly Taps Metis TechBio’s AI to Steer Medicines to Target Tissues
Metis TechBio will use AI to design tissue-targeted drug carriers for Eli Lilly. Upfront cash is low double-digit millions; milestones run up to $1.1bn.
Latest on TSN
Explore the TSN Atlas: Every topic we cover, mapped. Click a bubble to dive in.
